News on lab-developed tests and emerging diagnostic technologies.
The assay runs on the firm's rapid molecular diagnostics instrument, the PCR One, in approximately 15 minutes.
The kits are designed for the self-collection of anterior nasal swab or saliva specimens by adults for use with SARS-CoV-2 tests.
On the back of a recently announced $3 million in funding, the firm has begun marketing its Urodiag kit to urologists throughout Europe.
For the three months ended March 31, the firm said that preliminary revenues are expected to be $36 million to $37 million compared to $31.1 million in 2020.
Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers.
